Literature DB >> 23348801

When does combining markers improve classification performance and what are implications for practice?

Aasthaa Bansal1, Margaret Sullivan Pepe.   

Abstract

When an existing standard marker does not have sufficient classification accuracy on its own, new markers are sought with the goal of yielding a combination with better performance. The primary criterion for selecting new markers is that they have good performance on their own and preferably be uncorrelated with the standard. Most often linear combinations are considered. In this paper, we investigate the increment in performance that is possible by combining a novel continuous marker with a moderately performing standard continuous marker under a variety of biologically motivated models for their joint distribution. We find that an uncorrelated continuous marker with moderate performance on its own usually yields only minimally improved performance. We identify other settings that lead to large improvements, including a novel marker that has very poor performance on its own but is highly correlated with the standard and a novel marker with poor to moderate performance that is highly correlated with the standard but only in one class category. These results suggest changing current strategies for identifying markers to be included in panels for possible combination. Using simulated and real datasets, we examine the merits of a broadened strategy that selects panels of markers as candidates on the basis of their joint performance with existing markers, compared with the standard strategy that selects markers on the basis of their marginal performance. We find that a broadened strategy can be fruitful but necessitates using studies with large numbers of subjects.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23348801      PMCID: PMC3893148          DOI: 10.1002/sim.5736

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Combining several screening tests: optimality of the risk score.

Authors:  Martin W McIntosh; Margaret Sullivan Pepe
Journal:  Biometrics       Date:  2002-09       Impact factor: 2.571

Review 2.  Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.

Authors:  Margaret Sullivan Pepe; Holly Janes; Gary Longton; Wendy Leisenring; Polly Newcomb
Journal:  Am J Epidemiol       Date:  2004-05-01       Impact factor: 4.897

3.  Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.

Authors:  Andreas P Berger; Martina Deibl; Hannes Steiner; Jasmin Bektic; Alexandre Pelzer; Robert Spranger; Helmut Klocker; Georg Bartsch; Wolfgang Horninger
Journal:  Prostate       Date:  2005-08-01       Impact factor: 4.104

4.  Generating longitudinal screening algorithms using novel biomarkers for disease.

Authors:  Martin W McIntosh; Nicole Urban; Beth Karlan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-02       Impact factor: 4.254

5.  Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk.

Authors:  Mitchell H Gail
Journal:  J Natl Cancer Inst       Date:  2008-07-08       Impact factor: 13.506

6.  Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers.

Authors:  S J Skates; F J Xu; Y H Yu; K Sjövall; N Einhorn; Y Chang; R C Bast; R C Knapp
Journal:  Cancer       Date:  1995-11-15       Impact factor: 6.860

7.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.

Authors:  Garnet L Anderson; Martin McIntosh; Lieling Wu; Matt Barnett; Gary Goodman; Jason D Thorpe; Lindsay Bergan; Mark D Thornquist; Nathalie Scholler; Nam Kim; Kathy O'Briant; Charles Drescher; Nicole Urban
Journal:  J Natl Cancer Inst       Date:  2009-12-30       Impact factor: 13.506

  7 in total
  14 in total

1.  Further insight into the incremental value of new markers: the interpretation of performance measures and the importance of clinical context.

Authors:  Kathleen F Kerr; Aasthaa Bansal; Margaret S Pepe
Journal:  Am J Epidemiol       Date:  2012-08-08       Impact factor: 4.897

Review 2.  Developing risk prediction models for kidney injury and assessing incremental value for novel biomarkers.

Authors:  Kathleen F Kerr; Allison Meisner; Heather Thiessen-Philbrook; Steven G Coca; Chirag R Parikh
Journal:  Clin J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 8.237

3.  First things first: risk model performance metrics should reflect the clinical application.

Authors:  Kathleen F Kerr; Holly Janes
Journal:  Stat Med       Date:  2017-12-10       Impact factor: 2.373

4.  Development and validation of a cardiovascular disease risk-prediction model using population health surveys: the Cardiovascular Disease Population Risk Tool (CVDPoRT).

Authors:  Douglas G Manuel; Meltem Tuna; Carol Bennett; Deirdre Hennessy; Laura Rosella; Claudia Sanmartin; Jack V Tu; Richard Perez; Stacey Fisher; Monica Taljaard
Journal:  CMAJ       Date:  2018-07-23       Impact factor: 8.262

5.  Combining large number of weak biomarkers based on AUC.

Authors:  Li Yan; Lili Tian; Song Liu
Journal:  Stat Med       Date:  2015-07-30       Impact factor: 2.373

6.  Independent validation test of the vote-counting strategy used to rank biomarkers from published studies.

Authors:  Brad A Rikke; Murry W Wynes; Leslie M Rozeboom; Anna E Barón; Fred R Hirsch
Journal:  Biomark Med       Date:  2015-07-30       Impact factor: 2.851

7.  Microsimulation model to predict incremental value of biomarkers added to prognostic models.

Authors:  Karol M Pencina; Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina
Journal:  J Am Med Inform Assoc       Date:  2018-10-01       Impact factor: 4.497

8.  Risk prediction for complex diseases: application to Parkinson disease.

Authors:  Taryn O Hall; Jia Y Wan; Ignacio F Mata; Kathleen F Kerr; Katherine W Snapinn; Ali Samii; John W Roberts; Pinky Agarwal; Cyrus P Zabetian; Karen L Edwards
Journal:  Genet Med       Date:  2012-12-06       Impact factor: 8.822

9.  Predicting Stroke Risk Based on Health Behaviours: Development of the Stroke Population Risk Tool (SPoRT).

Authors:  Douglas G Manuel; Meltem Tuna; Richard Perez; Peter Tanuseputro; Deirdre Hennessy; Carol Bennett; Laura Rosella; Claudia Sanmartin; Carl van Walraven; Jack V Tu
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

10.  High expression of nucleoporin 133 mRNA in bone marrow CD138+ cells is a poor prognostic factor in multiple myeloma.

Authors:  Soushi Ibata; Masayoshi Kobune; Shohei Kikuchi; Masahiro Yoshida; Shogo Miura; Hiroto Horiguchi; Kazuyuki Murase; Satoshi Iyama; Kohichi Takada; Koji Miyanishi; Junji Kato
Journal:  Oncotarget       Date:  2018-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.